The following CARPS have all passed phase 2 with flying colours...

The following CARPS have all passed phase 2 with flying colours and passed efficacy potential and still failed to get a response

- CN-105 peptide
- R18 peptide
- NA-1 peptide

The AGN also known as R18D peptide has shown in mice to help save Exons but the function results failed. The peptide has repeated itself multiple times under this drug class and failed because you want to be a smart fella, whatever drug has ever made it to market it always targets specific receptor that have a important function for that disease or condition. These peptides try and target multiple receptors at once. Name me one drug approved by the FDA approved on market that targets a ton of receptors at once? Plain stupidity and it’s been the flaw of this peptide since the results from the other peptides have been coming out in recent years

AGN was always flawed ever since NA-1 and CN-105 failed in phase 3, in the past 2 years of which AGN was comparing itself to when it first listed back in 2021. Now they don’t even mention the other peptides. Any fool would make that link. Now phase 2 is in the bag and hence why I’m here. The flaw has always been at phase 3 with these peptides in the same class